FindTrial
Sign In

Clinical performance study of a new diagnostic test for drug sensitivity evaluation in metastatic colorectal cancer

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519600-27-00
Acronym
DSEE-CRC
Enrollment
75
Registered
2025-04-29
Start date
2025-10-28
Completion date
Unknown
Last updated
2025-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic colorectal cancer

Brief summary

Proportion of patients with a successful biopsy yielding a µCAN report.

Detailed description

Proportion of patients with a successful biopsy yielding a µCAN report within 56 days (8 weeks)., Proportion of patients with a successful biopsy yielding a µCAN report with at least one drug therapy nomination., Frequency, intensity and seriousness of adverse events (AEs) related to device or study procedures., Frequency and nature of device deficiencies (DD)., Device user experience questionnaire.

Interventions

DRUGFLUOROURACIL

Sponsors

Oncosyne AS
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Proportion of patients with a successful biopsy yielding a µCAN report.—

Secondary

MeasureTime frame
Proportion of patients with a successful biopsy yielding a µCAN report within 56 days (8 weeks)., Proportion of patients with a successful biopsy yielding a µCAN report with at least one drug therapy nomination., Frequency, intensity and seriousness of adverse events (AEs) related to device or study procedures., Frequency and nature of device deficiencies (DD)., Device user experience questionnaire.—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026